<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2757ac31-07b3-4df2-80cc-f9918606c08a"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to useÂ HEMICLOR<sup>TM </sup>safely and effectively. See full prescribing information for HEMICLOR.<br/>
      <br/>HEMICLOR (chlorthalidone) tablets, for oral use<br/>Initial U.S. Approval: 1960</title>
   <effectiveTime value="20250327"/>
   <setId root="3f0f3ee0-f5a6-4bda-8160-a77744e9fa46"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="833250017"/>
            <name>Ingenus Pharmaceuticals, LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <id root="1.3.6.1.4.1.519.1" extension="118256253"/>
                  <name>PRM Pharma LLC</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="964680206"/>
                        <name>Ingenus Pharmaceuticals NJ, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50742-285" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="6e9b4294-f9a7-4fec-a4aa-5cad7b41271a"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <title/>
               <text/>
               <effectiveTime value="20250327"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="50742-285" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>HEMICLOR</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>chlorthalidone</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="12.5" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Q0MQD1073Q" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CHLORTHALIDONE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Q0MQD1073Q" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CHLORTHALIDONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="776XM7047L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CALCIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H8AV0SQX4D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50742-285-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250317"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50742-285-90" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250317"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250317"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA218647" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText>White to off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48347" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RECTANGLE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="6" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">I</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="L1e035a85-a1a3-48ae-bf4e-1d86d9b97303">
               <id root="717740b1-eb45-416a-a1b7-940b91930d99"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text/>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>HEMICLORÂ is a thiazide-like diuretic indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (<linkHtml href="#L5c113a39-0e70-490f-9620-d9caede7c3f4">1.1</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="L5c113a39-0e70-490f-9620-d9caede7c3f4">
                     <id root="3b26c40d-1414-457e-b6e4-877e8b414131"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Hypertension</title>
                     <text>
                        <paragraph>HEMICLORÂ is indicated for the treatment of hypertension in adults, to lower blood pressure.</paragraph>
                        <paragraph>Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs.</paragraph>
                        <paragraph>Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Programâs Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).</paragraph>
                        <paragraph>Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.</paragraph>
                        <paragraph>Elevated systolic or diastolic blood pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.</paragraph>
                        <paragraph>HEMICLORÂ may be used alone or in combination with other antihypertensives.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L611f24cc-62c6-4cb2-8368-0e69cb06f470">
               <id root="9e7b4aa8-f79b-4cd0-b888-b54d20abdf08"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text/>
               <effectiveTime value="20250312"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>The recommended starting doseÂ is 12.5 mg or 25 mg orally once dailyÂ (<linkHtml href="#L3e7c3ce2-287e-4617-91fb-23283f6fdfdf">2.1</linkHtml>).</item>
                           <item>Dose may be doubled after 2 to 4 weeks as needed based on individual response, up to a maximal dose of 100 mg once dailyÂ (<linkHtml href="#L3e7c3ce2-287e-4617-91fb-23283f6fdfdf">2.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="L3e7c3ce2-287e-4617-91fb-23283f6fdfdf">
                     <id root="16fc1c07-4386-4f8a-a2cf-a86a7b1f8a95"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1Â Recommended Dosage</title>
                     <text>
                        <paragraph>Therapy should be initiated with the lowest possible dose. The recommended adult initial dose of HEMICLOR is 12.5 mg or 25 mg given orally with food once daily. Double the dosage every 2 to 4 weeks as needed based on individual patient response, up to a maximum of 100 mg once daily. Dosage above 100 mg daily usually does not increase effectiveness.</paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="La0819856-378a-4535-bb6c-37db76baa114">
               <id root="36a27b84-a830-4478-ace0-719740a38381"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Each HEMICLORÂ tablet contains 12.5 mg of chlorthalidone. The tablets are white to off-white, modified rectangle shaped tablets debossed with âIâ on one side andÂ plain on the other side.</paragraph>
               </text>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Tablets: 12.5 mg (<linkHtml href="#La0819856-378a-4535-bb6c-37db76baa114">3</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L6f2e326a-fe16-4847-8647-e8a53f7cadb5">
               <id root="5bbaf9f6-5a2f-4150-8760-202c9b55ff39"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Chlorthalidone is contraindicated in patients with anuria, or hypersensitivity to chlorthalidone or other sulfonamide-derived drugs.</paragraph>
               </text>
               <effectiveTime value="20250312"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Anuria (<linkHtml href="#L6f2e326a-fe16-4847-8647-e8a53f7cadb5">4</linkHtml>).</item>
                           <item>Hypersensitivity to chlorthalidone or other sulfonamide-derived drugsÂ (<linkHtml href="#L6f2e326a-fe16-4847-8647-e8a53f7cadb5">4</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L9ba22c93-09c5-425d-bd7a-e262f4267d30">
               <id root="212fbdab-9719-44ef-8b4f-a63096a3287b"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20250312"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Acute Kidney Injury: Patients with pre-existing kidney disease may be at higher risk.Â (<linkHtml href="#L10d61050-9a9f-4e64-b6b6-ea53db6d6af3">5.1</linkHtml>).</item>
                           <item>Electrolyte Abnormalities: Monitor serum electrolytes periodically (<linkHtml href="#L662e7701-526f-432d-a599-2d3fd4744d02">5.2</linkHtml>).</item>
                           <item>Metabolic Disturbances (<linkHtml href="#L9e1280d1-6cf9-4ffc-a130-539adb81f06d">5.3</linkHtml>).</item>
                           <item>Systemic Lupus Erythematosus (<linkHtml href="#L5e3e5409-9f3b-48f4-8c98-daca79ed18ab">5.4</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="L10d61050-9a9f-4e64-b6b6-ea53db6d6af3">
                     <id root="cbd4e58e-f229-478e-be7a-5d1c96f3c16e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1Â Acute Kidney Injury</title>
                     <text>
                        <paragraph>Monitor kidney function periodically. Diuretics can cause hypovolemia which may precipitate acute kidney injury.Â Patients with chronic kidney disease, heart failure, or volume depletion may be at particular risk of developing acute renal failure on Chlorthalidone. Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in kidney function while on chlorthalidone.</paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
               <component>
                  <section ID="L662e7701-526f-432d-a599-2d3fd4744d02">
                     <id root="e9db1fee-6a34-4659-ab2f-0fbfc0f79df8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Electrolyte Abnormalities</title>
                     <text>
                        <paragraph>Chlorthalidone can cause hypokalemia, hyponatremia, hypochloremic alkalosis, and hypomagnesemia. Hypomagnesemia can result in hypokalemia which appears difficult to treat despite potassium repletion. Hypokalemia is dose dependent. Monitor and correct serum electrolytes prior to use and monitor periodically.</paragraph>
                     </text>
                     <effectiveTime value="20240521"/>
                  </section>
               </component>
               <component>
                  <section ID="L9e1280d1-6cf9-4ffc-a130-539adb81f06d">
                     <id root="65baf7f4-877a-45a7-a71b-a5a65c5dd841"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3Â Metabolic Disturbances</title>
                     <text>
                        <paragraph>Chlorthalidone may increase blood sugar levels, affect diabetes control, and cause changes in the need for diabetes medication.</paragraph>
                        <paragraph>Chlorthalidone may raise serum levels of cholesterol and triglycerides. Monitor blood sugar and lipid levels.</paragraph>
                        <paragraph>Chlorthalidone may raise the serum uric acid level due to reduced clearance of uric acid and may cause or exacerbate hyperuricemia and precipitate gout in susceptible patients. Increases in serum uric acid are dose related.</paragraph>
                        <paragraph>Chlorthalidone decreases urinary calcium excretion and may cause elevations of serum calcium. Monitor calcium levels in patients with hypercalcemia receiving Chlorthalidone.</paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
               <component>
                  <section ID="L5e3e5409-9f3b-48f4-8c98-daca79ed18ab">
                     <id root="9e9c12ba-b7d1-4bed-8b16-2414c448214c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Systemic Lupus Erythematosus</title>
                     <text>
                        <paragraph>The possibility of exacerbation or activation of systemic lupus erythematosus has been reported with thiazide diuretics, which are structurally related to chlorthalidone. However, systemic lupus erythematosus has not been reported following chlorthalidone administration.</paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lbbcf4b26-3ec3-4e00-a94e-4b94525fcee2">
               <id root="dca43332-520b-41bb-8252-1b57ec41bf66"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are described in more detail elsewhere in the label;</paragraph>
                  <list listType="unordered">
                     <item>Acute Kidney Injury<content styleCode="italics"> [see <linkHtml href="#L10d61050-9a9f-4e64-b6b6-ea53db6d6af3">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Electrolyte Abnormalities<content styleCode="italics"> [see <linkHtml href="#L662e7701-526f-432d-a599-2d3fd4744d02">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Metabolic Disturbances <content styleCode="italics">[see <linkHtml href="#L9e1280d1-6cf9-4ffc-a130-539adb81f06d">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                  </list>
                  <paragraph>The following adverse reactions have been observed with chlorthalidone, but there is not enough systematic collection of data to support an estimate of their frequency.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Gastrointestinal System Reactions: </content>anorexia, gastric irritation, nausea, vomiting, cramping, diarrhea, constipation, jaundice (intrahepatic cholestatic jaundice), pancreatitis.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Central Nervous System Reactions: </content>dizziness, paresthesias, headache.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Hematologic Reactions: </content>leukopenia, agranulocytosis, thrombocytopenia, aplastic anemia.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Dermatologic-Hypersensitivity Reactions: </content>purpura, photosensitivity, rash, urticaria, necrotizing angiitis (vasculitis) (cutaneous vasculitis), Lyellâs syndrome (toxic epidermal necrolysis).</paragraph>
                  <paragraph>
                     <content styleCode="italics">Cardiovascular Reaction: </content>Orthostatic hypotension.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Other Adverse Reactions: </content>muscle spasm, weakness, restlessness, impotence, xanthopsia.</paragraph>
               </text>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most frequently expected adverse drug reactions among patients receiving thiazide-like diuretics are electrolyte abnormalitiesÂ and metabolic disturbances (<linkHtml href="#Lbbcf4b26-3ec3-4e00-a94e-4b94525fcee2">6</linkHtml>).</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contactÂ Ingenus Pharmaceuticals, LLC at 1-877-748-1970 or FDA at 1-800-FDA-1088 or </content>
                           <content styleCode="bold">www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L28fca1be-9f3a-4215-a4c8-864edbc22d1a">
               <id root="be788305-895f-4373-98f6-c4f5d8bb9233"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Effect of chlorthalidone on other drugsÂ  </content>
                  </paragraph>
                  <paragraph>Insulin requirements in diabetic patients may be increased, decreased or unchanged. Higher dosage of oral hypoglycemic agents may be required.</paragraph>
                  <paragraph>Chlorthalidone mayÂ increase the responsiveness to tubocurarine.</paragraph>
                  <paragraph>Chlorthalidone may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.</paragraph>
                  <paragraph>Lithium renal clearance is reduced by chlorthalidone, increasing the risk of lithium toxicity. Monitor serum lithium levels during concomitant use.</paragraph>
               </text>
               <effectiveTime value="20240521"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Insulin requirements and oral hypoglycemic agent dosages may require adjustmentsÂ (<linkHtml href="#L28fca1be-9f3a-4215-a4c8-864edbc22d1a">7</linkHtml>).</item>
                           <item>Possible increased responsiveness to tubocurarine (<linkHtml href="#L28fca1be-9f3a-4215-a4c8-864edbc22d1a">7</linkHtml>).</item>
                           <item>Possible decreased arterial responsiveness to norepinephrine (<linkHtml href="#L28fca1be-9f3a-4215-a4c8-864edbc22d1a">7</linkHtml>).</item>
                           <item>Lithium renal clearance is reduced by chlorthalidone, increasing the risk of lithium toxicity (<linkHtml href="#L28fca1be-9f3a-4215-a4c8-864edbc22d1a">7</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L769d96f8-17f7-47bd-8b98-95a1d96c5d05">
               <id root="642279c9-cc60-48c6-9e8a-316fa1f827b2"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20250312"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Pregnancy: May cause fetal harm (<linkHtml href="#Ledfea98c-bdf3-413a-bba3-dc76c267fa04">8.1</linkHtml>).</item>
                           <item>Lactation: Breastfeeding not recommended (<linkHtml href="#L826ce28f-cb41-4c2f-81ab-37c6e0c1f36b">8.2</linkHtml>).</item>
                           <item>Geriatric Use: No overall difference in responses versus younger patients, but care should be taken in dose selection in patients with impaired renal function (<linkHtml href="#L74842dad-daf5-4915-a90d-34f5195c2d00">8.5</linkHtml>).</item>
                           <item>Hepatic Impairment: Alterations on fluid and electrolyte balance should be monitored in patients with hepatic impairment (<linkHtml href="#L2a15756e-47ce-4394-972c-3817f0aa9285">8.6</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Ledfea98c-bdf3-413a-bba3-dc76c267fa04">
                     <id root="7257e5e6-4b46-42d2-be8e-ef5962208c46"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Available data over decades from observational studies and reports with chlorthalidone use in pregnant women have not identified a drug-associated risk of major birth defects or miscarriage. However, adverse fetal outcomes, including fetal or neonatal jaundice, thrombocytopenia, hypoglycemia, and electrolyte abnormalities have been reported following maternal use of thiazide diuretics <content styleCode="italics">(see Clinical Considerations). </content>Chlorthalidone should not be used as first-line therapy to treat hypertension in pregnancy. Advise pregnant women of the potential risk to a fetus.</paragraph>
                        <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 12.5 to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease-associated maternal and/or embryo/fetal risk</content>
                        </paragraph>
                        <paragraph>Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage). Hypertension increases the fetal risk for intrauterine growth restriction and stillbirth.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Fetal/Neonatal Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Thiazides can cross the placenta, and concentrations reached in the umbilical vein approach those in the maternal plasma. Thiazides, like other diuretics, can cause placental hypoperfusion. Use of thiazides during pregnancy is associated with a risk of fetal or neonatal jaundice, thrombocytopenia, hypoglycemia, and electrolyte abnormalities. Thiazides do not prevent or alter the course of EPH (Edema, Proteinuria, Hypertension) gestosis (pre-eclampsia) and should not be used as first-line therapy to treat hypertension in pregnant women.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Reproduction studies have been performed in the rat and the rabbit and have revealed no evidence of harm to the fetus due to chlorthalidone. The available data do not allow the calculation of comparisons between the exposure of chlorthalidone observed in animal studies to the systemic exposure that would be expected in humans.</paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
               <component>
                  <section ID="L826ce28f-cb41-4c2f-81ab-37c6e0c1f36b">
                     <id root="0f1f8394-1c40-4185-a766-1470db27e625"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Chlorthalidone is present in human milk. There is no information regarding the effects of chlorthalidone on the breastfed infant or the effects on milk production. Because of the potential for chlorthalidone accumulation which may lead to serious adverse reactions in the breastfed infant (such as jaundice, thrombocytopenia, hyperglycemia, electrolyte abnormalities), advise patients that breastfeeding is not recommended during treatment with chlorthalidone.</paragraph>
                     </text>
                     <effectiveTime value="20240521"/>
                  </section>
               </component>
               <component>
                  <section ID="L58c6061e-d3b8-4843-9251-8127ec3f5b74">
                     <id root="d03e0306-eab6-4c68-8f6d-790f6d3d424d"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in children have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20240521"/>
                  </section>
               </component>
               <component>
                  <section ID="L74842dad-daf5-4915-a90d-34f5195c2d00">
                     <id root="c2a8188f-47f7-4241-b59b-3b677d9f39b4"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                        <paragraph>Chlorthalidone is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</paragraph>
                     </text>
                     <effectiveTime value="20240521"/>
                  </section>
               </component>
               <component>
                  <section ID="L2a15756e-47ce-4394-972c-3817f0aa9285">
                     <id root="6a539348-f7dd-4b2d-a144-7e0b4e7bf706"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Hepatic Impairment</title>
                     <text>
                        <paragraph>Minor alterations of fluid and electrolyte balance may precipitate hepatic coma in patients with impaired hepatic function or progressive liver disease.</paragraph>
                     </text>
                     <effectiveTime value="20240521"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L27987516-97c2-4717-a53c-0834410d75d9">
               <id root="e0f7f697-e391-4d47-81a7-3615eaafd750"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Symptoms of acute overdosage include nausea, weakness, dizziness and disturbances of electrolyte balance. The oral LD50 of the drug in the mouse and the rat is more than 25,000 mg/kg body weight. The minimum lethal dose (MLD) in humans has not been established. There is no specific antidote but gastric lavage is recommended, followed by supportive treatment. Where necessary, this may include intravenous dextrose-saline with potassium, administered with caution.</paragraph>
               </text>
               <effectiveTime value="20230726"/>
            </section>
         </component>
         <component>
            <section ID="L95397ab9-5abb-410c-8ffb-dabf8a8ae282">
               <id root="629af71c-91d1-4f9b-9d28-7daaaceccb15"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>HEMICLORÂ (chlorthalidone) is an antihypertensive/diuretic supplied as 12.5 mg tablets for oral use. Chlorthalidone is a monosulfamyl diuretic that differs chemically from thiazide diuretics in that a double ring system is incorporated in its structure. It is a racemic mixture of 2-chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl) benzenesulfonamide, with the following structural formula:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L23264592-1d4c-4aac-91cf-5a990df6ac4f"/>
                  </paragraph>
                  <paragraph>Molecular Formula: C<sub>14</sub>H<sub>11</sub>ClN<sub>2</sub>O<sub>4</sub>SÂ  Â Â Â Â Â Â Molecular Weight: 338.8 g/mol</paragraph>
                  <paragraph>Chlorthalidone is practically insoluble in water, soluble in acetone and in methanol, slightly soluble in 96% ethanol, practically insoluble in dichloromethane. It dissolves in diluted solutions of alkali hydroxides.</paragraph>
                  <paragraph>EachÂ HEMICLORÂ tablet contains the following inactive ingredients: calcium stearate, colloidal silicon dioxide, microcrystalline cellulose, pregelatinized starch and sodium starch glycolate.</paragraph>
               </text>
               <effectiveTime value="20250313"/>
               <component>
                  <observationMedia ID="L23264592-1d4c-4aac-91cf-5a990df6ac4f">
                     <text>structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="structure001.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L60da79dd-3614-4718-a1b4-7f5b79d28ad3">
               <id root="c95d5cf7-4113-4ef5-a631-9a2a45150c60"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <text/>
               <effectiveTime value="20240521"/>
               <component>
                  <section ID="Lc664d980-141c-4c44-a69e-9708b70d2297">
                     <id root="93028c79-09ed-4883-8b17-cb9a0381dda0"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Chlorthalidone is a long-acting oral diuretic with antihypertensive activity. Chlorthalidone produces diuresis with increased excretion of sodium and chloride. The site of action appears to be the cortical diluting segment of the ascending limb of Henleâs loop of the nephron. The diuretic effects of chlorthalidone lead to decreased extracellular fluid volume, plasma volume, cardiac output, total exchangeable sodium, glomerular filtration rate, and renal plasma flow. Although the mechanism of action of chlorthalidone and related drugs is not wholly clear, sodium and water depletion appear to provide a basis for its antihypertensive effect.</paragraph>
                     </text>
                     <effectiveTime value="20240521"/>
                  </section>
               </component>
               <component>
                  <section ID="L106e2b60-8050-4960-a524-d4b698890cc2">
                     <id root="c0138043-6a96-49e6-a01c-bf68c3f7caf4"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>The diuretic action of chlorthalidone commences a mean of 2.6 hours after dosing and continues for up to 72 hours. Chlorthalidone produces dose-related reductions in serum potassium levels, elevations in serum uric acid and blood glucose, and it can lead to decreased sodium and chloride levels.</paragraph>
                     </text>
                     <effectiveTime value="20240521"/>
                  </section>
               </component>
               <component>
                  <section ID="L4ae0aa11-6887-4ec8-be26-7ac41fd7985a">
                     <id root="48f80258-c0e7-4b1e-a008-939defff2b0a"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Approximately 75 percent of the drug is bound to plasma proteins, 58 percent of the drug being bound to albumin. This is caused by an increased affinity of the drug to erythrocyte carbonic anhydrase. Data are not available regarding concentration of the drug in body fluids, degree of uptake by a particular organ or in the fetus, or passage across the blood-brain barrier.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination </content>
                        </paragraph>
                        <paragraph>The mean plasma half-life of chlorthalidone is about 40 to 60 hours.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Data are not available regarding percentage of dose as unchanged drug and metabolites.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Chlorthalidone is eliminated primarily as unchanged drug in the urine. Nonrenal routes of elimination have yet to be clarified.</paragraph>
                     </text>
                     <effectiveTime value="20240521"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lc5a0205d-a85e-405e-ad65-577a62f5e70c">
               <id root="6bd0723a-93df-41b1-be40-a183105359e6"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20240521"/>
               <component>
                  <section ID="Ld6100bf3-289d-4b6e-8be3-243b09adad02">
                     <id root="96165347-1fae-4c8d-bca4-a694f3d871bb"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>No carcinogenicity study has been conducted with chlorthalidone. Â </paragraph>
                        <paragraph>Mutagenesis: Chlorthalidone demonstrated no potential for mutagenic effects at non-cytotoxic concentrations and is considered not to pose a mutagenic risk to humans.</paragraph>
                        <paragraph>Impairment of Fertility: Chlorthalidone at a dosage of 100 mg/kg had no effect on fertility in rats.</paragraph>
                     </text>
                     <effectiveTime value="20240521"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L1a43d687-618e-4b2a-9859-c533c3e6e3f7">
               <id root="248e6aee-9ecb-4edd-bca1-9f65d6c49920"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The efficacy of a once daily dose of chlorthalidone 12.5 mg for the treatment of hypertension in adults is derived from a published randomized, double-blind, multinational, study (Sica et al, 2012)<footnote ID="Lb41bbd18-9085-4b69-ab5c-1866a050f4e2">Sica D, Bakris GL, White WB, et al. <content styleCode="italics">J.Clin. Hypertens.</content> 2012;14(5):284-292</footnote>Â along with other supportive studies from the published literature.</paragraph>
               </text>
               <effectiveTime value="20250328"/>
            </section>
         </component>
         <component>
            <section ID="Lc9d065f4-493a-4529-b462-dfa8a9ca646e">
               <id root="5f8924af-2552-4f2a-983c-76d6ffec8689"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>HEMICLORÂ 12.5 mg tablets are supplied as white to off-white, modified rectangle shaped tablets debossed with âIâ on one side andÂ plain on the other side. HEMICLORÂ tablets are supplied as bottles of 30 tablets, 90 tablets, 100 tablets and 1,000 tablets.</paragraph>
                  <paragraph>NDC Number:Â 50742-285-30, Bottles of 30.</paragraph>
                  <paragraph>NDC Number:Â 50742-285-90, Bottles of 90.</paragraph>
                  <paragraph>NDC Number: 50742-285-01, Bottles of 100.</paragraph>
                  <paragraph>NDC Number: 50742-285-10, Bottles of 1,000.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Storage</content>
                  </paragraph>
                  <paragraph>Store at 20ÂºC to 25ÂºC (68ÂºF to 77ÂºF) [See USP Controlled Room Temperature].</paragraph>
                  <paragraph>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</paragraph>
               </text>
               <effectiveTime value="20250327"/>
            </section>
         </component>
         <component>
            <section ID="L558601a9-5513-4f8e-9a3b-35609df9957a">
               <id root="c217f17e-dbb1-4b0f-9d0e-70971e93ba18"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Patients should inform their doctor if they have had an allergic reaction to chlorthalidone or other diuretics; kidney disease; gout; been taking lithium carbonate.</paragraph>
                  <paragraph>Patients should be cautioned to contact their physician if they experience any of the following symptoms of potassium loss: excess thirst, tiredness, drowsiness, restlessness, muscle pains or cramps, nausea, vomiting or increased heart rate or pulse.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Pregnancy</content>
                  </paragraph>
                  <paragraph>Advise a pregnant woman of the potential risk to a fetus. Advise females of reproductive potential to inform their prescriber of a known or suspected pregnancy <content styleCode="italics">[see<linkHtml href="#Ledfea98c-bdf3-413a-bba3-dc76c267fa04"> Use in Specific Populations (8.1)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>Advise females not to breastfeed during treatment with chlorthalidone <content styleCode="italics">[see <linkHtml href="#L826ce28f-cb41-4c2f-81ab-37c6e0c1f36b">Use in Specific Populations (8.2)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured for:</content>
                  </paragraph>
                  <paragraph>Ingenus Pharmaceuticals, LLC<br/>Orlando, FL 32811</paragraph>
                  <paragraph>Rev. 03/2025<br/>555800</paragraph>
               </text>
               <effectiveTime value="20250327"/>
            </section>
         </component>
         <component>
            <section ID="L1bfbc579-20c2-4b34-a465-1892de12019b">
               <id root="655ef53e-88ff-4769-b446-2b55b32cf121"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Principal Display Panel -Â 30 Tablets</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 50742-285-30</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Hemi</content>
                     <content styleCode="bold">clor<sup>TM</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(chlorthalidone) Tablets USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">12.5 mg</content>
                  </paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>
                     <content styleCode="bold">30 Tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">ingenus</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L9ed8a3b1-a7b3-4094-974f-71c9ab83284e"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250328"/>
               <component>
                  <observationMedia ID="L9ed8a3b1-a7b3-4094-974f-71c9ab83284e">
                     <text>label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lf343811f-cbce-4af0-8bb2-9fc20541b267">
               <id root="ec3f1f10-ea85-4000-91ee-8202e6d63626"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Principal Display Panel - 90 Tablets</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 50742-285-90</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Hemi</content>
                     <content styleCode="bold">clor<sup>TM</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(chlorthalidone) Tablets USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">12.5 mg</content>
                  </paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>
                     <content styleCode="bold">90 Tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">ingenus</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L404238c1-ec81-4391-b491-0be88a5ad3a8"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250328"/>
               <component>
                  <observationMedia ID="L404238c1-ec81-4391-b491-0be88a5ad3a8">
                     <text>label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>